MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
MaxCyte (NASDAQ: MXCT) reported Q2 2024 financial results and updated full-year guidance. Total revenue reached $10.4 million, up 15% year-over-year. Core business revenue declined 9% to $7.6 million, while SPL Program-related revenue surged 279% to $2.9 million. The company signed five new SPL clients year-to-date, bringing the total to 28. MaxCyte affirmed its 2024 core business revenue guidance of flat to 5% growth and increased SPL Program-related revenue guidance to approximately $6 million. The company expects to end 2024 with at least $180 million in total cash, cash equivalents, and investments.
MaxCyte (NASDAQ: MXCT) ha riportato i risultati finanziari del secondo trimestre 2024 e ha aggiornato le previsioni per l'intero anno. Il fatturato totale ha raggiunto 10,4 milioni di dollari, con un aumento del 15% rispetto all'anno precedente. Il fatturato dell'attività principale è diminuito del 9% a 7,6 milioni di dollari, mentre il fatturato relativo al programma SPL è aumentato del 279% a 2,9 milioni di dollari. L'azienda ha firmato cinque nuovi clienti SPL dall'inizio dell'anno, portando il totale a 28. MaxCyte ha confermato le previsioni di fatturato per l'attività principale del 2024, prevedendo una crescita piatta fino al 5% e ha aumentato le previsioni di fatturato relative al programma SPL a circa 6 milioni di dollari. L'azienda prevede di chiudere il 2024 con almeno 180 milioni di dollari in totale di liquidità, equivalenti di liquidità e investimenti.
MaxCyte (NASDAQ: MXCT) informó los resultados financieros del segundo trimestre de 2024 y actualizó las previsiones para todo el año. Los ingresos totales alcanzaron 10,4 millones de dólares, un incremento del 15% interanual. Los ingresos del negocio principal cayeron un 9% a 7,6 millones de dólares, mientras que los ingresos relacionados con el programa SPL se dispararon un 279% a 2,9 millones de dólares. La compañía firmó cinco nuevos clientes SPL en lo que va del año, llevando el total a 28. MaxCyte reafirmó su guía de ingresos del negocio principal para 2024, pronosticando un crecimiento plano de hasta el 5% y aumentó la guía de ingresos relacionados con el programa SPL a aproximadamente 6 millones de dólares. La empresa espera cerrar 2024 con al menos 180 millones de dólares en efectivo, equivalentes de efectivo e inversiones.
MaxCyte (NASDAQ: MXCT)는 2024년 2분기 재무 결과를 보고하고 연간 가이드를 업데이트했습니다. 총 수익은 1,040만 달러에 달하며, 전년 대비 15% 증가했습니다. 핵심 사업 수익은 9% 감소하여 760만 달러에 이르고, SPL 프로그램 관련 수익은 279% 급증하여 290만 달러에 달했습니다. 올해 들어 다섯 명의 신규 SPL 고객과 계약을 체결하여 총 28명이 되었습니다. MaxCyte는 2024년 핵심 사업 수익 가이드를 변동 없음에서 5% 성장으로 reaffirmed하고, SPL 프로그램 관련 수익 예측을 약 600만 달러로 증가시켰습니다. 회사는 2024년을 마감할 때 총 1억 8천만 달러 이상의 현금, 현금성 자산 및 투자를 보유할 것으로 예상하고 있습니다.
MaxCyte (NASDAQ: MXCT) a annoncé les résultats financiers du deuxième trimestre 2024 et mis à jour son orientation annuelle. Le chiffre d'affaires total a atteint 10,4 millions de dollars, soit une augmentation de 15 % par rapport à l'année précédente. Les revenus de l'activité principale ont diminué de 9 % pour s'élever à 7,6 millions de dollars, tandis que les revenus liés au programme SPL ont grimpé de 279 % à 2,9 millions de dollars. La société a signé Cinq nouveaux clients SPL depuis le début de l'année, portant le total à 28. MaxCyte a confirmé ses prévisions de revenus pour l'activité principale de 2024, tablant sur une croissance stable de 5 %, et a augmenté ses prévisions de revenus liés au programme SPL à environ 6 millions de dollars. L'entreprise prévoit de clôturer l'année 2024 avec au moins 180 millions de dollars en liquidités, équivalents de liquidités et investissements.
MaxCyte (NASDAQ: MXCT) hat die Finanzresultate für das zweite Quartal 2024 veröffentlicht und die Jahresprognose aktualisiert. Der Gesamterlös betrug 10,4 Millionen USD, was einem Anstieg von 15% im Vergleich zum Vorjahr entspricht. Der Umsatz des Kerngeschäfts fiel um 9% auf 7,6 Millionen USD, während die Erlöse aus dem SPL-Programm um 279% auf 2,9 Millionen USD anstiegen. Das Unternehmen hat fünf neue SPL-Kunden seit Jahresbeginn gewonnen, womit sich die Gesamtzahl auf 28 erhöht. MaxCyte bestätigte die Umsatzprognose für 2024 für das Kerngeschäft mit einer Wachstumsprognose von bis zu 5% und erhöhte die Prognose für die Erlöse aus dem SPL-Programm auf etwa 6 Millionen USD. Das Unternehmen erwartet, 2024 mit mindestens 180 Millionen USD an Gesamtliquidität, liquiden Mitteln und Investitionen abzuschließen.
- Total revenue increased by 15% year-over-year to $10.4 million in Q2 2024
- SPL Program-related revenue grew by 279% to $2.9 million in Q2 2024
- Five new Strategic Platform License (SPL) clients signed year-to-date, bringing the total to 28
- Increased SPL Program-related revenue guidance to approximately $6 million for 2024
- Raised expected year-end cash, cash equivalents, and investments to at least $180 million
- Core business revenue declined by 9% to $7.6 million in Q2 2024
- Cell therapy revenue decreased by 6% to $6.2 million in Q2 2024
- Drug discovery revenue fell by 18% to $1.4 million in Q2 2024
- Net loss of $9.4 million in Q2 2024, although improved from $10.5 million in Q2 2023
MaxCyte's Q2 2024 results show mixed performance. While total revenue grew
The company's gross margin remained stable at
The affirmed guidance for core business revenue and increased SPL Program-related revenue forecast suggest cautious optimism. Investors should monitor the company's ability to convert its growing SPL partnerships into sustainable revenue growth.
MaxCyte's position as a leading cell engineering platform provider is strengthened by the addition of five new Strategic Platform License (SPL) partners in 2024, bringing the total to 28. This expansion into diverse indications demonstrates the versatility and demand for MaxCyte's technology in the rapidly evolving cell therapy landscape.
The company's focus on commercial execution in cell therapy is crucial, as this sector represents the largest portion of core revenue. However, the
Investors should closely watch the progress of MaxCyte's SPL partners, particularly in late-stage clinical trials, as their success could significantly impact MaxCyte's future revenue streams.
ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced its financial results for the second quarter ended June 30, 2024, and updates its 2024 guidance.
Second Quarter and Recent Highlights
- Total revenue of
$10.4 million in the second quarter of 2024, an increase of15% over the second quarter of 2023. - Core business revenue of
$7.6 million in the second quarter of 2024, a decline of9% over the second quarter of 2023. - Strategic Platform License (SPL) Program-related revenue was
$2.9 million for the second quarter of 2024, an increase of279% over the second quarter of 2023. - Five new SPL clients signed year-to-date. Legend Biotech signed in May, Be Biopharma signed in March, and Wugen, Imugene, and Lion TCR signed in January. The total number of SPL partners now stands at 28.
- Total cash, cash equivalents and investments were
$199.8 million as of June 30, 2024.
“We are pleased by our second quarter results and our business performance in the first half of 2024 and remain confident we will deliver our full year guidance. We continue to drive commercial execution in cell therapy and believe that we remain the premier cell engineering platform in the industry,” said Maher Masoud, President and CEO at MaxCyte.
“Since the beginning of the year, MaxCyte has signed five new SPLs, which includes recently signed Legend Biotech, along with Be Biopharma, in March 2024. Our total number of SPLs now stands at 28, highlighting the demand for our platform and our continued expansion into a range of different indications. As our clients continue to progress through the clinic, we believe we continue to provide the best electroporation platform with the best support for their programs. We remain excited by continued demand for our platform and our role in enabling a growing set of next-generation cell therapies.”
The following table provides details regarding the sources of our revenue for the periods presented.
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| June 30, | June 30, | ||||||||||||||||||||||
| 2024 | 2023 | % | 2024 | 2023 | % | ||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Cell therapy | $ | 6,218 | $ | 6,637 | ( | $ | 12,633 | $ | 12,611 | ||||||||||||||
| Drug discovery | 1,357 | 1,652 | ( | 3,129 | 3,450 | ( | |||||||||||||||||
| Program-related | 2,854 | 754 | 6,008 | 1,558 | |||||||||||||||||||
| Total revenue | $ | 10,429 | $ | 9,043 | $ | 21,770 | $ | 17,619 | |||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| June 30, | June 30, | ||||||||||||||||||||||
| 2024 | 2023 | % | 2024 | 2023 | % | ||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Instrument | $ | 1,762 | $ | 2,126 | ( | $ | 3,690 | $ | 4,315 | ( | |||||||||||||
| PAs | 2,974 | 3,293 | ( | 6,406 | 5,893 | ||||||||||||||||||
| Lease | 2,610 | 2,667 | ( | 5,214 | 5,476 | ( | |||||||||||||||||
| Other | 229 | 203 | 452 | 377 | |||||||||||||||||||
| Total Core Revenue | $ | 7,575 | $ | 8,289 | ( | $ | 15,762 | $ | 16,061 | ( | |||||||||||||
In addition to revenue, management regularly reviews key business metrics to evaluate our business, measure performance, identify trends affecting our business, formulate financial projections and make strategic decisions. As of the dates presented, these key metrics were as follows:
| As of June 30, | |||||||
| 2024 | 2023 | ||||||
| Installed base of instruments (sold or leased) | 723 | 654 | |||||
| Three Months Ended June 30, | |||||||
| 2024 | 2023 | ||||||
| Core Revenue Generated by SPL Clients as % of Core Revenue | 51 | % | 49 | % | |||
Second Quarter 2024 Financial Results
Total revenue for the second quarter of 2024 was
Core business revenue (sales and leases of instrument and disposables to cell therapy and drug discovery customers, excluding SPL Program-related revenue) for the second quarter of 2024 was
Cell therapy revenue for the second quarter of 2024 was
SPL Program-related revenue was
Gross profit for the second quarter of 2024 was
Operating expenses for the second quarter of 2024 were
Second quarter 2024 net loss was
First Half 2024 Financial Results
Total revenue for the first half of 2024 was
Core business revenue (sales and leases of instrument and disposables to cell therapy and drug discovery customers but excluding SPL Program-related revenue) for the first half of 2024 was
Cell therapy revenue for the first half of 2024 was
SPL Program-related revenue was
Gross profit for the first half of 2024 was
Operating expenses for the first half of 2024 were
First half 2024 net loss was
2024 Revenue Guidance
MaxCyte affirms 2024 revenue guidance for core business revenue and increases SPL Program-related revenue guidance.
MaxCyte continues to expect full year 2024 core business revenue to be flat to
MaxCyte now expects to end 2024 with at least
Webcast and Conference Call Details
MaxCyte will host a conference call today, August 6, 2024, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.
Non-GAAP Financial Measures
This press release contains EBITDA, which is a non-GAAP measure defined as earnings before interest income and expense, taxes, depreciation and amortization. MaxCyte believes that EBITDA provides useful information to management and investors relating to its results of operations. The company’s management uses this non-GAAP measure to compare the company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The company believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.
Management does not consider EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of EBITDA is that it excludes significant expenses that are required by GAAP to be recorded in the company’s financial statements. In order to compensate for these limitations, management presents EBITDA together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of net loss, the most comparable GAAP financial measure, to EBITDA is included at the end of this release. MaxCyte urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about the Company’s projected full-year total revenue, core revenue, and SPL program revenue and statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," “contemplate,” "target,” the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; our expectation that our partners will have access to capital markets to develop and commercialize their cell therapy programs; our financial performance and capital requirements; and the amount and adequacy of our cash resources.
These and other risks and uncertainties are described in greater detail in Item 1A , entitled "Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on or about March 12, 2024, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
venes@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
| MaxCyte, Inc. Unaudited Consolidated Balance Sheets (in thousands, except share and per share amounts) | |||||||
| June 30, | December 31, | ||||||
| 2024 | 2023 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 37,513 | $ | 46,506 | |||
| Short-term investments, at amortized cost | 119,817 | 121,782 | |||||
| Accounts receivable, net | 4,581 | 5,778 | |||||
| Inventory | 11,159 | 12,229 | |||||
| Prepaid expenses and other current assets | 2,577 | 3,899 | |||||
| Total current assets | 175,647 | 190,194 | |||||
| Investments, non-current, at amortized cost | 42,481 | 42,938 | |||||
| Property and equipment, net | 21,720 | 23,513 | |||||
| Right-of-use asset - operating leases | 11,008 | 11,241 | |||||
| Other assets | 640 | 388 | |||||
| Total assets | $ | 251,496 | $ | 268,274 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 953 | $ | 743 | |||
| Accrued expenses and other | 7,076 | 11,269 | |||||
| Operating lease liability, current | 878 | 774 | |||||
| Deferred revenue, current portion | 3,368 | 5,069 | |||||
| Total current liabilities | 12,275 | 17,855 | |||||
| Operating lease liability, net of current portion | 17,650 | 17,969 | |||||
| Other liabilities | 310 | 283 | |||||
| Total liabilities | 30,235 | 36,107 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity | |||||||
| Preferred stock, | — | — | |||||
| Common stock, | 1,048 | 1,040 | |||||
| Additional paid-in capital | 414,912 | 406,925 | |||||
| Accumulated deficit | (194,699 | ) | (175,798 | ) | |||
| Total stockholders’ equity | 221,261 | 232,167 | |||||
| Total liabilities and stockholders’ equity | $ | 251,496 | $ | 268,274 | |||
| MaxCyte, Inc. Unaudited Consolidated Statements of Operations (in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue | $ | 10,429 | $ | 9,043 | $ | 21,770 | $ | 17,619 | |||||||
| Cost of goods sold | 1,488 | 1,376 | 2,891 | 2,376 | |||||||||||
| Gross profit | 8,941 | 7,667 | 18,879 | 15,243 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 5,619 | 5,664 | 12,297 | 11,711 | |||||||||||
| Sales and marketing | 6,617 | 6,436 | 13,981 | 12,732 | |||||||||||
| General and administrative | 7,639 | 7,663 | 14,742 | 15,161 | |||||||||||
| Depreciation and amortization | 1,034 | 977 | 2,102 | 1,890 | |||||||||||
| Total operating expenses | 20,909 | 20,740 | 43,122 | 41,494 | |||||||||||
| Operating loss | (11,968 | ) | (13,073 | ) | (24,243 | ) | (26,251 | ) | |||||||
| Other income: | |||||||||||||||
| Interest income | 2,593 | 2,561 | 5,342 | 4,857 | |||||||||||
| Total other income | 2,593 | 2,561 | 5,342 | 4,857 | |||||||||||
| Net loss | $ | (9,375 | ) | $ | (10,512 | ) | $ | (18,901 | ) | $ | (21,394 | ) | |||
| Basic and diluted net loss per share | $ | (0.09 | ) | $ | (0.10 | ) | $ | (0.18 | ) | $ | (0.21 | ) | |||
| Weighted average shares outstanding, basic and diluted | 104,639,239 | 103,063,606 | 104,364,498 | 102,955,422 | |||||||||||
| MaxCyte, Inc. Unaudited Consolidated Statements of Cash Flows (in thousands) | |||||||
| Six Months ended June 30, | |||||||
| 2024 | 2023 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (18,901 | ) | $ | (21,394 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation and amortization | 2,192 | 1,988 | |||||
| Non-cash lease expense | 233 | 190 | |||||
| Net book value of consigned equipment sold | 21 | 66 | |||||
| Loss on disposal of fixed assets | 361 | - | |||||
| Stock-based compensation | 6,579 | 6,796 | |||||
| Credit loss (recovery) expense | (130 | ) | 230 | ||||
| Change in excess/obsolete inventory reserve | 137 | - | |||||
| Amortization of discounts on investments | (3,665 | ) | (3,641 | ) | |||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | 1,327 | 3,990 | |||||
| Accounts receivable - TIA | - | 1,912 | |||||
| Inventory | 833 | (2,542 | ) | ||||
| Prepaid expense and other current assets | 1,322 | 724 | |||||
| Other assets | (321 | ) | 212 | ||||
| Accounts payable, accrued expenses and other | (3,497 | ) | (1,039 | ) | |||
| Operating lease liability | (215 | ) | 112 | ||||
| Deferred revenue | (1,701 | ) | (2,020 | ) | |||
| Other liabilities | 27 | (13 | ) | ||||
| Net cash used in operating activities | (15,398 | ) | (14,429 | ) | |||
| Cash flows from investing activities: | |||||||
| Purchases of investments | (79,353 | ) | (104,955 | ) | |||
| Maturities of investments | 85,440 | 163,320 | |||||
| Purchases of property and equipment | (1,098 | ) | (2,065 | ) | |||
| Proceeds from sale of equipment | — | 9 | |||||
| Net cash provided by investing activities | 4,989 | 56,309 | |||||
| Cash flows from financing activities: | |||||||
| Proceeds from exercise of stock options | 1,151 | 1,613 | |||||
| Proceeds from issuance of common stock under employee stock purchase plan | 265 | - | |||||
| Net cash provided by financing activities | 1,416 | 1,613 | |||||
| Net (decrease) increase in cash and cash equivalents | (8,993 | ) | 43,493 | ||||
| Cash and cash equivalents, beginning of period | 46,506 | 11,064 | |||||
| Cash and cash equivalents, end of period | $ | 37,513 | $ | 54,557 | |||
| Unaudited Reconciliation of Net Loss to EBITDA (in thousands) | |||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| (in thousands) | |||||||||||||||
| Net loss | $ | (9,375 | ) | $ | (10,512 | ) | $ | (18,901 | ) | $ | (21,394 | ) | |||
| Depreciation and amortization expense | 1,081 | 1,026 | 2,192 | 1,988 | |||||||||||
| Interest income | (2,593 | ) | (2,561 | ) | (5,342 | ) | (4,857 | ) | |||||||
| Income taxes | — | — | — | — | |||||||||||
| EBITDA | $ | (10,887 | ) | $ | (12,047 | ) | $ | (22,051 | ) | $ | (24,263 | ) | |||
%
FAQ
What was MaxCyte's (MXCT) total revenue for Q2 2024?
How many new Strategic Platform License (SPL) clients did MaxCyte (MXCT) sign in 2024 so far?
What is MaxCyte's (MXCT) updated guidance for SPL Program-related revenue in 2024?
How much cash, cash equivalents, and investments does MaxCyte (MXCT) expect to have by the end of 2024?
